Dermėja - Company finances
|
EUR
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 1,945 | 2,960 | 3,450 | 4,050 | 4,420 |
| Profit before tax | - | - | - | - | - |
| Net profit | -86 | -313 | -305 | -11 | 68 |
| Equity | 797 | 484 | 179 | 168 | 236 |
| Liabilities | 0 | 0 | 0 | 1,250 | 0 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 797 | 484 | 179 | 1,418 | 236 |
| Total assets | 797 | 484 | 179 | 1,418 | 236 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +52.2% | +16.6% | +17.4% | +9.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -10.8% | -64.7% | -170.4% | -0.8% | 28.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -10.8% | -64.7% | -170.4% | -6.5% | 28.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -4.4% | -10.6% | -8.8% | -0.3% | 1.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 7.4 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Dermėja - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-07-01 | 2022-07-31 | 50.95 |
Dermėja - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Dermėja is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2023-05-11 | 2026-09-02 | 1.16 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Dermeja, MB (code 303069015) is a Lithuanian small partnership engaged in medical specialists activities. In 2025, the latest financial year, the company generated EUR 4.4K in revenue, up 9.1% year on year, and moved back into profit with net profit of EUR 68 after a near break-even result in 2024 and a loss of EUR 305 in 2023. The 2025 profit margin was 1.5%, indicating modest but positive profitability. Over the last three years, revenue increased steadily from EUR 3.5K in 2023 to EUR 4.0K in 2024 and EUR 4.4K in 2025, which represents 28.1% growth over two years. The balance sheet remains very small: total assets were EUR 236 in 2025, matching equity at EUR 236, which gives an equity ratio of 100.0%. In 2024, total assets were EUR 1.4K and liabilities EUR 1.2K, while equity stood at EUR 168. The reported ROE and ROA for 2025 were both 28.8%, and asset turnover was 18.73x, reflecting a high level of sales relative to the asset base.